chufangao/CTO huggingface dataset:
Clinical trial NCT02700841: Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Official title: A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated prematurely due to poor recruitment.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-09
Primary completion date: 2022-12-21
Completion date: 2022-12-21
Plan to share individual participant data: NO
Clinical trial NCT02594111: Colchicine in Percutaneous Coronary Intervention
Official title: Anti-inflammatory Therapy During Percutaneous Coronary Intervention
Acronym: Colchicine-PCI
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 714.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-05-30
Primary completion date: 2019-08-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT05512949: Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
Official title: A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 229.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-09
Primary completion date: 2022-12-01
Completion date: 2023-10-19
Clinical trial NCT03345797: Evaluation of Testosterone Nasal Gel in Hypogonadal Boys
Official title: A Multicenter, Open Label, Variable Dose, Two Arm Pilot Paediatric Phase 1 PK Study to Evaluate Testosterone Nasal Gel (4.5% w/w) in Hypogonadal Boys
Sponsor: Acerus Pharmaceuticals Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of patients and commercial reasons
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-01
Primary completion date: 2020-04-11
Completion date: 2022-04-11
Plan to share individual participant data: NO
Clinical trial NCT04890353: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
Official title: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
Sponsor: Xuanwu Hospital, Beijing (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The interim analysis of another associated study is not very effective
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2023-02-08
Completion date: 2023-02-28
Clinical trial NCT03990974: Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
Official title: Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in Hepatocellular Carcinoma After Liver Resection: A Multi-center, Randomized, Open-labelled Trial.
Acronym: HCC
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: There were difficulties in implementation
Enrollment: 458.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-06-30
Completion date: 2021-07-31
Clinical trial NCT02819518: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Official title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 882.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-07-27
Primary completion date: 2021-06-15
Completion date: 2023-10-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02756663: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Official title: A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Acronym: PANORAMA-5
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-12-31
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Clinical trial NCT05506930: ITM vs QL for Pediatric Open Lower Abdominal Procedures
Official title: Intrathecal Morphine Versus Bilateral Quadratus Lumborum Blocks for Perioperative Analgesia in Pediatric Patients Undergoing Open Lower Abdominal Procedures: A Prospective Randomized Trial
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was stopped early based on the anecdotal evidence from a surgeon who felt one group was experiencing more side effects than the other. Exposing pediatric patients who would be assigned to the inferior arm was difficult to justify ethically.
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-17
Primary completion date: 2024-05-09
Completion date: 2024-05-10
Clinical trial NCT04473950: The Effect of Chronic Pain on Delay Discounting in Methadone Patients
Official title: The Effect of Chronic Pain on Delay Discounting in Methadone Patients
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The COVID-19 Pandemic prevented us from meeting target goals.
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-08
Primary completion date: 2022-10-06
Completion date: 2022-10-06
Plan to share individual participant data: YES
IPD sharing description: Data will be made available to the public through presentation at scientific meetings and research publications in peer-reviewed journals. I have routinely kept an open policy to share data with the scientific and medical community upon request, and this policy will be continued with the present project.
IPD time frame: Data will become available after publication of the main study results.
Clinical trial NCT02334722: 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Official title: A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-05
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Baseline population: Subjects were screened against eligibility criteria. Subjects with a history of seizures, depression or use of psychiatric medications, Beck-Depression Inventory score over 14, biopsy only or other factors were determined ineligible. Potential participants who may have been eligible also declined participation.
Plan to share individual participant data: NO
Clinical trial NCT01891994: Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Official title: Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-06-28
Primary completion date: 2017-10-16
Completion date: 2022-08-24
Clinical trial NCT03736785: A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Official title: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 399.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-15
Primary completion date: 2020-02-18
Completion date: 2020-02-18
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04430985: FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
Official title: FOLFOX + Immunotherapy With Intrahepatic Administration of Oxaliplatin for Patients With Multiple Non-resectable Liver Metastasis From Colorectal Cancer
Acronym: IMMUNOX
Sponsor: Herlev Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Problems identifying eligble patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-30
Primary completion date: 2021-09-06
Completion date: 2021-09-06
Plan to share individual participant data: NO
Clinical trial NCT04011033: Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Official title: Study of Adoptive Transfer of Invariant Natural Killer T Cells Combined With TAE/TACE to Treat Unresectable Hepatocellular Carcinoma (HCC): Phase II Clinical Trial
Sponsor: Beijing YouAn Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-01
Primary completion date: 2020-03-01
Completion date: 2023-10-01
Limitations and caveats: One limitation of our study is that patients only received two cycles of TAE and the duration of iNKT therapy was only 3 months; thus, our study was not long enough to adequately assess OS. A second limitation was the small sample size, but our promising data prompts future studies in larger cohorts to more thoroughly delineate how iNKT cell therapy can be used in the context of TACE/TAE to improve therapeutic options for patients with unresectable HCC.
Plan to share individual participant data: NO
Clinical trial NCT05133180: Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Official title: A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 104.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-19
Primary completion date: 2022-09-22
Completion date: 2022-12-19
Baseline population: The Full Analysis Set (FAS) population included all patients who were randomized and received at least one dose of the investigational product.
Clinical trial NCT04859517: Evaluation of ADG20 for the Prevention of COVID-19
Official title: A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
Acronym: EVADE
Sponsor: Invivyd, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.
Enrollment: 2582.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-27
Primary completion date: 2022-11-04
Completion date: 2022-11-04
Plan to share individual participant data: NO
Clinical trial NCT03850795: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Official title: PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Hinova Pharmaceuticals USA, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Terminated by Sponsor for various factors including prolonged duration and enrollment challenges
Enrollment: 104.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-15
Primary completion date: 2024-06-28
Completion date: 2024-06-28
Plan to share individual participant data: NO
Clinical trial NCT03733444: A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Official title: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Acronym: ISABELA2
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The benefit-risk profile no longer supports continuing the study
Enrollment: 781.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-05
Primary completion date: 2021-03-30
Completion date: 2021-03-30
Baseline population: Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of investigation product (IP).
Plan to share individual participant data: NO
Clinical trial NCT04239872: Fluoride Retention in the Mouth of Older Adults
Official title: Optimizing Fluoride Retention in the Mouth of Older Adults With Distinct Salivary Flow Rates
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-11
Primary completion date: 2021-04-05
Completion date: 2021-04-05
Limitations and caveats: The amount of biofilm collected from participants at the different time points was not enough for all the analyses planned in a number of occasions. This accounts for the lack of data for the calcium concentration in the biofilm fluid.~This experiment was conducted during the COVID-19 pandemic.
Plan to share individual participant data: NO
Clinical trial NCT02895373: PGE1 as Additive Anticoagulant in ECMO-Therapy
Official title: A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)
Acronym: ECMO_PGE1
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of recruitment and study procedures
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-31
Primary completion date: 2021-05-31
Completion date: 2021-07-31
Plan to share individual participant data: NO
IPD sharing description: Data will be published in a peer-reviewed journal, individual data will not be made publicly available except by a direct request to the PI (in an anonymized fashion)
Clinical trial NCT04308785: A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Official title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Study to Investigate the Efficacy and Safety of Atezolizumab With or Without Tiragolumab as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed After Chemoradiotherapy
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor's decision was based on the negative results of SKYSCRAPER-02.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2023-07-25
Completion date: 2023-07-25
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04077398: Volume vs Concentration: Quadratus Lumborum Blocks With High Volume/Low Concentration or Low Volume/ High Concentration in Nephrectomies
Official title: Volume Versus Concentration: a Prospective, Double Blind, Parallel Study to Compare the Clinical Effectiveness of Bilateral Quadratus Lumborum Blocks Using High Volume/Low Concentration or Low Volume/ High Concentration Local Anesthetic in Nephrectomies
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: covid interrupted initial start, then trainees involved finished program and no one took it on
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-22
Primary completion date: 2021-01-01
Completion date: 2021-08-01
Plan to share individual participant data: NO
IPD sharing description: there is no plan to share individual participant data.
Clinical trial NCT04870606: Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
Official title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness
Sponsor: Suzhou Kintor Pharmaceutical Inc, (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 733.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-05
Primary completion date: 2022-01-24
Completion date: 2022-04-06
Plan to share individual participant data: NO
Clinical trial NCT01415674: Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients
Official title: Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients
Acronym: PREDICTOR
Sponsor: UNICANCER (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-01-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT03881371: A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Official title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Sponsor: Zambon SpA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 307.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2021-08-20
Completion date: 2021-08-20
Baseline population: Safety population were included all patients who provided informed consent and received at least 1 dose or partial dose of study drug.
Clinical trial NCT04362085: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Official title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
Sponsor: Unity Health Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 465.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-11
Primary completion date: 2021-05-10
Completion date: 2021-10-14
Plan to share individual participant data: NO
Clinical trial NCT03729284: A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
Official title: A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA) COMPARED WITH CYMBALTA(REGISTERED) ( 60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FASTED CONDITIONS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: This study has been cancelled prior to FSFV due to business reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-30
Primary completion date: 2020-06-07
Completion date: 2020-06-07
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT01007994: Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Official title: Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-11-30
Primary completion date: 2020-01-31
Completion date: 2020-08-31
Clinical trial NCT05195762: 12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi
Official title: 12-Week Clinical Study to Determine the Safety, Tolerability, and Clinical Effect of NFX-179 Gel in Subjects With Epidermal Nevi
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsored declined to proceed
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-06-30
Primary completion date: 2024-06-30
Completion date: 2024-12-31
Plan to share individual participant data: NO
IPD sharing description: We will only be sharing participant data with the sponsor, Nflection Therapeutics.
Clinical trial NCT05644587: Novel Induction to Buprenorphine/Naloxone
Official title: Novel Induction to Buprenorphine/Naloxone: A Quasi-Experimental Study With Comparison Group
Sponsor: Bicycle Health (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low enrollment numbers
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-06
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Plan to share individual participant data: NO